Infliximab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT 1 and ACT 2

Sandborn, J.F. Colombel, Willem J.S. deVilliers, Gary R. Lichtenstein(University of Pennsylvania), Brian G. Feagan(Western University), Daniel Rachmilewitz(Hadassah Academic College), S. Hanauer(University of Illinois Chicago), Walter Reinisch(Medical University of Vienna), Anders Olson(University of California, Los Angeles), B E Sands(Icahn School of Medicine at Mount Sinai), D. H. Present, Paul Rutgeerts(KU Leuven), Jewel Johanns(Johnson & Johnson (United States)), Jiajie Lu(Sichuan University)
Inflammatory Bowel Diseases
January 1, 2008
10.1097/00054725-200801001-00006
Cited by 5

Related Papers

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k